Vanda Pharmaceuticals | VNDA - Debt


Vanda Pharmaceuticals reported $4.96M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.62M 275K Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.31B 571M Dec/2025
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.33B 1.43B Dec/2025
Takeda JPY 4.85T 208B Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Veracyte USD 39.65M 799K Dec/2025